1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Hold On TG’s Program Stems From Existing – Not New – Concerns

‘Sub-par’ Disclosure Draws Analyst Finger Wagging

 
• By Alaric DeArment

TG expects overall survival hazard ratios to move closer to those of existing CLL drugs. Some analysts called a drop in the company’s shares overblown.

Digital illustration of Cancer cell in colour background
TG disclosed a partial clinical hold on its program to develop Ukoniq/ublituximab in NHL and CLL • Source: Shutterstock

The partial clinical hold on TG Therapeutics, Inc.’s program for PI3K-delta inhibitor Ukoniq (umbralisib) combined with CD20-directed ublituximab – together nicknamed U2 – does not appear to be about any new concerns about Ukoniq. However, it does highlight concerns about the PI3K class overall and the method by which the company disclosed the hold drew criticism.

TG’s CEO Michael Weiss revealed in a fireside chat at B. Riley Securities’ 2022 Virtual Oncology Investor Conference on 27...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Regeneron Wins Long-Sought FDA Nod For Lynozyfic In Myeloma

 
• By Alaric DeArment

The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

In Vivo CAR-T Interest Grows With AbbVie Acquisition

 
• By Andrew McConaghie

Acquiring Capstan gives AbbVie a stake in two competing in vivo CAR-T delivery platforms, with the field's first readouts expected in 2026.

More from Therapy Areas

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.